The dementia treatment for children is available in the US, with funding for UK children unclear.
The dementia treatment for children is available in the US, with funding for UK children unclear.
A family affected by Sanfilippo syndrome raised millions of dollars for research. The Food and Drug Administration just approved a gene therapy the support helped make possible.
Bobby's mum, Sophie, says she wants him to "get the most out of his short life'" after his diagnosis.
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.
An affected mother says she cannot think of a worse diagnosis for a child than childhood dementia.
Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.
Ultragenyx on Thursday set a U.S. list price of $3.95 million for its newly approved gene therapy Fayuvi, launching one of the world's most expensive drugs.
FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.
- FDA approval represents a monumental milestone for patients with MPS IIIA and validates Abeona’s foundational R&D and clinical development efforts - - Ultragenyx successfully brought a life-changing therapy across the finish line for MPS IIIA patients and families - CLEVELAND, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today congratulated Ultrage
Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.
FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx The Company received a Priority R
RARE investors are now awaiting an FDA decision on UX111, the company’s one-time gene therapy for Sanfilippo syndrome type A.
Rocket Companies (NYSE: RKT) today announced that Alessio Sanfilippo has been named Chief Executive Officer of Redfin, effective immediately. Sanfilippo joins Redfin from Meta, where he served as Vice President of Insights for Reality Labs.
Rocket (RKT) has named Alessio Sanfilippo as chief executive officer of its Redfin unit, effective i
John B. Sanfilippo & Son (NASDAQ:JBSS) outlined plans to expand its snack bar manufacturing business while continuing to build on its private-label nut and trail mix operations, during a presentation at the IDEAS Conference. The company, a fourth-generation family-managed processor, marketer and di
On August 20, John B. Sanfilippo & Sons (NASDAQ:JBSS) reported a fiscal year that looked strong on paper and a fourth quarter that told a messier story. Full-year net sales hit $1.18 billion, a record, while fourth-quarter diluted earnings per share fell 38.3% to $0.71. Volume returned to growth for the first time in five […]
Detailed price information for John B Sanfilippo (JBSS-Q) from The Globe and Mail including charting and trades.
The latest analyst update on John B. Sanfilippo & Son cuts fair value from US$109.00 to US$100.00, which is about an 8% reduction in the price target. Analysts link this shift to how they balance stronger revenue assumptions with more cautious views on margins and risk, and to where they see the stock on the current risk and reward spectrum. As you read on, you will see how these moving parts shape the evolving narrative around John B. Sanfilippo & Son and what to watch next. Stay updated as...
This is the newest page. Registered accounts read further back.